Skip to main content
MEDIPOSTCO.,LTD. logo

MEDIPOSTCO.,LTD. — Investor Relations & Filings

Ticker · 078160 ISIN · KR7078160009 KO Manufacturing
Open in API
Filings indexed 366 across all filing types
Latest filing 2024-04-23 M&A Activity
Country KR South Korea
Listing KO 078160

About MEDIPOSTCO.,LTD.

https://en.medi-post.co.kr/

MEDIPOST is a biotechnology company specializing in the research, development, and commercialization of stem cell therapeutics and regenerative medicine. The company focuses on addressing unmet medical needs for incurable diseases through its proprietary stem cell platform technology. Its core operations include a cord blood banking service and the development of allogeneic stem cell therapies. Key commercialized products include CARTISTEM®, a treatment for knee cartilage defects and osteoarthritis, and PNEUMOSTEM®, a preventive therapy for bronchopulmonary dysplasia in premature infants. The company's clinical pipeline features next-generation injectable treatments for conditions such as osteoarthritis and diabetic nephropathy.

Recent filings

Filing Released Lang Actions
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a regulatory filing from Medipost regarding the 'Decision to Acquire Shares and Equity Securities of Another Corporation' (타법인주식및출자증권취득결정). This is a standard corporate disclosure in the Korean market (DART system) detailing a capital investment in a subsidiary (MEDIPOST, Inc. USA). Since this document describes a specific corporate action involving capital allocation and investment in another entity, it falls under the category of 'Regulatory Filings' (RNS) as it is a specific disclosure of a material event that does not fit into the more specific categories like M&A (which usually implies a merger or takeover) or Share Issue (which refers to the company's own capital structure changes).
2024-04-23 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a regulatory filing from MediPost regarding the decision to acquire shares and equity securities of another corporation (MediPost CDMO). It details the acquisition amount, purpose (expansion into the North American CDMO market), and board approval. This type of disclosure regarding corporate investment and capital allocation is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like M&A (which usually implies a merger or takeover of a third party) or Share Issue (which relates to the company's own capital structure).
2024-04-23 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (AGM) for Medipost. It details the voting outcomes for agenda items such as financial statement approval, director appointments, and remuneration limits. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2024-03-28 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including the number of shares, exercise price, and vesting conditions. Since this relates to the issuance of new shares/capital changes via stock options, it falls under the 'Share Issue/Capital Change' category.
2024-03-28 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details specific changes to the company's board of directors, including the resignation of one outside director and the appointment of a new one. This falls directly under the category of Board/Management Information.
2024-03-28 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Medipost titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit results, including the auditor's opinion, key financial data (assets, liabilities, equity, revenue, profit/loss), and capital status for the fiscal year. While it contains audit-related information, it is a standard regulatory disclosure announcement (DART filing in Korea) summarizing the audit outcome rather than the full, multi-page audit report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-03-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.